Plus a study that shows looks at availability and pricing at cash-pay pharmacies
And why the IRA's first round of price controls won't tell us much about CMS thinking
And a must-read Health Affairs piece on how to improve value assessment
And a Novo exec makes clear that obesity-med prices are going down
And CMS will pilot a new way for Medicaid to pay for gene therapy
And a must-read piece about why the cost-effectiveness analyses of the future will show drugs are a great deal
And other reasons why the next 10 days in DrugPricingLand are going to be so intense
Plus: am I naive for being amazed that Optum is making loans to health care providers?
And I'm still stuck on the Arnold Ventures net-price denialism
Plus a must-read letter to the CBO from No Patient Left Behind
Plus some musings on why news-you-can-use around drug pricing is so often shallow
And Mark Cuban convinces me (mostly) that maybe transparency alone could fix the drug-price debate
